Test intended to diagnose and monitor patients with AML.
Xenomics granted Asuragen coexclusive, worldwide rights to incorporate NPM1 technology into Asuragen’s molecular diagnostic products. Under the terms of this agreement, Asuragen will have the right to develop, manufacture, and market products for the diagnosis, stratification, and monitoring of patients with acute myeloid leukemia (AML).
A recent discovery, for which Xenomics holds exclusive rights, showed that many AML patients have mutations in the nucleophosmin (NPM1) gene, a favorable marker for clinical outcome. It is hoped that the results of such a test will help physicians select patients with a good prognosis of benefiting from intensive chemotherapy.
The NPM1 mutation may also be used to monitor AML patients for residual disease during chemotherapy.